Literature DB >> 20331820

Bullous skin lesions in a patient undergoing chronic hemodialysis.

Madhavi E Ryali1, William L Whittier.   

Abstract

Porphyria cutanea tarda (PCT) is a vesiculobullous skin disorder characterized by a defect in heme biosynthesis. Reduced activity of the hepatic enzyme uroporphyrinogen decarboxylase (URO-D) results in accumulation of photosensitive porphyrins; this ultimately leads to the skin fragility and blistering that is characteristic of this disease. The majority of cases of PCT are associated with acquired deficiencies of the enzyme URO-D, secondary to hepatic injury precipitated by medications or infections. Less commonly, PCT has been documented in patients with end-stage renal disease. The pathogenesis of PCT in long-term hemodialysis (HD) has been attributed to many factors, but the following mechanisms have been implicated: (i) decreased hepatic URO-D activity due to suppressive effects of iron and other hepatotoxins and (ii) poor porphyrin clearance by renal replacement therapies. We report a case of PCT that developed in a patient on maintenance HD for 4 years. He had a history of hepatitis C and evidence of iron overload. However, as the patient was anemic, therapeutic phlebotomy was problematic and therefore erythrocyte-stimulating agents were maximized to mobilize iron stores and allow phlebotomy. With this treatment, the patient's skin lesions improved in conjunction with decreasing ferritin levels.

Entities:  

Mesh:

Year:  2010        PMID: 20331820     DOI: 10.1111/j.1525-139X.2009.00672.x

Source DB:  PubMed          Journal:  Semin Dial        ISSN: 0894-0959            Impact factor:   3.455


  2 in total

Review 1.  Cutaneous manifestations of ESRD.

Authors:  Timur A Galperin; Antonia J Cronin; Kieron S Leslie
Journal:  Clin J Am Soc Nephrol       Date:  2013-10-10       Impact factor: 8.237

Review 2.  Cutaneous Manifestations of Chronic Kidney Disease, Dialysis and Post-Renal Transplant: A Review.

Authors:  Vivek Goel; Abheek Sil; Anupam Das
Journal:  Indian J Dermatol       Date:  2021 Jan-Feb       Impact factor: 1.494

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.